H2S-releasing metformin hybrid keeps glucose-lowering activity while adding vascular protection in diabetes models
- Met-ITC joins metformin to an H2S-releasing isothiocyanate, aiming to add vascular benefit without losing antidiabetic action.
- Computational profiling suggested better permeability than metformin; glucose-lowering activity persisted in liver cells and diabetic mice.
- In endothelial and smooth muscle cells it limited oxidative stress, cell death and senescence more effectively than metformin, and relaxed rat aortic rings with or without endothelium.
💡 Points Based on the abstract
A hybrid only earns a next study if the H2S arm adds something metformin can't. Here the rat aortic relaxation is the cleanest proof of that, but it's an isolated-tissue effect at unspecified exposure. I'd want PK showing intact hybrid versus released ITC and H2S in vivo, plus a metformin-matched db/db comparison on vascular endpoints, and checks on ITC reactivity and off-target thiol effects.